Phase III HOPE-B: Etranacogene Dezaparvovec Gene Therapy in Adults With Severe or Moderately Severe Hemophilia B

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Initial results from HOPE-B, the largest phase III study of gene therapy for hemophilia B to date, show etranacogene dezaparvovec yields clinically meaningful levels of factor IX activity within 6 months.
Format: Microsoft PowerPoint (.ppt)
File Size: 441 KB
Released: December 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

On-demand webcast of a live symposium at THSNA 2022 with experts discussing the management of immune thrombocytopenia, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil
Program Director
Catherine M. Broome, MD Cindy Neunert, MD, MSCS
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 15, 2022 Expired: September 14, 2023

Downloadable slideset on the key teaching points and considerations in the management of ITP, from Clinical Care Options (CCO)

Catherine M. Broome, MD David J. Kuter, MD, DPhil Cindy Neunert, MD, MSCS Released: August 26, 2022

A short downloadable slideset touching on key points in the treatment of hemophilia A & B, including extended half-life factor replacement, nonfactor therapies, and therapies to restore the hemostatic balance, from Clinical Care Options (CCO)

Glaivy Batsuli, MD Allison Wheeler, MD, MSCI Guy A. Young, MD Released: August 26, 2022

Downloadable slideset on the initial treatment considerations in the management of ITP, from Clinical Care Options (CCO)

Cindy Neunert, MD, MSCS Released: August 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings